First Trust Advisors
TCRT icon

First Trust Advisors’s Alaunos Therapeutics TCRT Stock Holding History

First Trust Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-498
Closed -$352K – 2425
2019
Q4 		$352K Buy
+498
New +$343K ﹤0.01% 2235

Other funds holding TCRT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Trust Advisors's TCRT Position: Q1 2020 in Review

First Trust Advisors sold out of Alaunos Therapeutics (TCRT) in Q1 2020, closing a stake of 498 shares — an estimated $352K sold.

First Trust Advisors first reported a position in TCRT in Q4 2019 and held it in 1 quarter. The position peaked at $352K in Q4 2019. 146 funds tracked by Wall St. Rank hold TCRT as of Q1 2020.

  • First Trust Advisors reported no remaining Alaunos Therapeutics position as of Q1 2020 after selling out during the quarter.
  • First Trust Advisors sold 498 Alaunos Therapeutics shares in Q1 2020, an estimated $352K.
  • First Trust Advisors first reported a position in Alaunos Therapeutics in Q4 2019 and held it in 1 quarter.
  • First Trust Advisors's Alaunos Therapeutics position peaked at $352K in Q4 2019.
  • 146 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2020.

Based on First Trust Advisors's 13F filing for Q1 2020, filed 6 May 2020.